Form 4: Glaukos Corp President & COO, Joseph E. Gilliam, Executes Stock Option and Sells Shares Under 10b5-1 Plan

Joseph E. Gilliam, President & COO of Glaukos Corporation, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• On April 5, 2024, Joseph E. Gilliam, President & COO of Glaukos Corporation, exercised stock options to acquire 2,457 shares of common stock at a price of $55.18 per share.
• Simultaneously, Gilliam sold 2,457 shares of Glaukos common stock at a weighted average price of $96.81 per share, with individual trades ranging from $96.57 to $97.17.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on March 7, 2023.
• Following these transactions, Gilliam directly owns 101,845 shares of Glaukos common stock, which includes 76,419 restricted stock units that have not yet vested.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports routine transactions under a pre-existing trading plan. There's no indication of positive or negative sentiment towards the company's prospects.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which can reassure investors that the sales were not based on insider information.

Risks

• Executive stock sales can sometimes be perceived negatively by investors, even when conducted under a 10b5-1 plan, as they may signal a lack of confidence in the company's future performance.

Industry Context

Insider transactions are common in publicly traded companies, and the use of 10b5-1 plans is a standard practice to allow insiders to sell shares while avoiding accusations of trading on non-public information. Investors often monitor these filings to gauge executive sentiment and potential future stock performance.

Comparison to Industry Standards

• Executive compensation packages often include stock options and restricted stock units to align management's interests with those of shareholders.
• The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies like Glaukos, including competitors in the ophthalmic medical device space such as Alcon and Johnson & Johnson Vision.
• These plans allow executives to diversify their holdings and manage personal finances without raising concerns about insider trading.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the potential dilution from the option exercise and the effect of the stock sale on the market price.

Key Dates